Dhillon Mandeep S, Patel Sandeep, John Rakesh
Department of Orthopaedics, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
SICOT J. 2017;3:27. doi: 10.1051/sicotj/2017004. Epub 2017 Mar 22.
Positive results have been uniformly observed by various researchers for platelet-rich plasma (PRP) in early osteoarthritis (OA) knee in the past few years. PRP has clearly demonstrated its supremacy in comparison to hyaluronic acid (HA) and placebo in various clinical trials and is undoubtedly the best option available for symptomatic treatment in early OA. The release of growth factors from PRP occurs immediately and lasts for around three weeks and the clinical effect tends to wane down by the end of the year. Prolonged and sustained release of growth factors from platelets could possibly help in much better biological healing and sustained clinical effects. PRP in combination with biocompatible carriers could be one way of achieving this. Gelatin hydrogel PRP and chitosan PRP seem to be promising based on early in vitro studies and animal studies. PRP in combination with hyaluronic acid also seems to be additive. This article intends to discuss the present status of the PRP, confusions surrounding its use, upcoming trends and ideas for improvising PRP for use early OA knees based on available evidence.
在过去几年中，不同的研究人员均在早期骨关节炎（OA）膝关节中观察到富血小板血浆（PRP）的积极效果。在各种临床试验中，PRP相较于透明质酸（HA）和安慰剂已明确显示出其优势，无疑是早期OA症状性治疗的最佳选择。PRP中生长因子的释放即刻发生，持续约三周，到年底临床效果往往会减弱。血小板生长因子的长期持续释放可能有助于实现更好的生物愈合和持续的临床效果。PRP与生物相容性载体结合可能是实现这一目标的一种方法。基于早期的体外研究和动物研究，明胶水凝胶PRP和壳聚糖PRP似乎很有前景。PRP与透明质酸联合使用似乎也具有相加作用。本文旨在根据现有证据，探讨PRP的现状、围绕其使用的困惑、未来趋势以及改进PRP用于早期OA膝关节的思路。
